Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
NCT05173298
Summary
The goal of this observational study is to learn about in patients with advanced hepatocellular carcinoma treated with atezoliozumab and bevacizumab. In this clinical study, we intend to analyze the multiomics data by analyzing the peripheral blood and tumor tissue before and after treatment of patients with advanced liver cancer receiving systemic drug treatment, and analyzing the correlation with the treatment. This is an exploratory study that aims to discover biomarkers that are highly correlated with treatment response.
Eligibility
The following two groups will be integrated and analyzed. The criteria for both groups are the same. Group 1. Prospective Group Inclusion Criteria * Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study. * Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests. * Patients who underwent an NGS test with advanced HCC tissues * Patients planning to receive atezolizumab and bevacizumab combination therapy * Patients with measurable lesions based on RECIST v1.1 * ECOG performance status 0 or 1 * Patients with a life expectancy of at least three months Exclusion Criteria * Patients who have systemic conditions accompanied by instability of vital signs, such as infections or organ failure * Those with mental/neurological conditions or dementia who have difficulties understanding and completing the consent form * Those who are assessed as not suitable for this study, at the discretion of the researcher Group 2. Retrospective Group Inclusion Criteria * Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study. * Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests. * Patients who underwent an NGS test with advanced HCC tissues * Patients have received atezolizumab and bevacizumab combination therapy * Patients with measurable lesions based on RECIST v1.1 * ECOG performance status 0 or 1 * Patients with a life expectancy of at least three months Exclusion criteria * Patients who have systemic conditions accompanied by instability of vital signs, such as infections or organ failure * Those with mental/neurological conditions or dementia who have difficulties understanding and completing the consent form * Those who are assessed as not suitable for this study, at the discretion of the researcher
Conditions4
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT05173298